Skip to main content

Table 1 Patient characteristics and total number of bone metastases with 18F-fluoride PET/CT uptake

From: Repeatability of quantitative parameters of 18F-fluoride PET/CT and biochemical tumour and specific bone remodelling markers in prostate cancer bone metastases

Patients’ ID Age at diagnosis Gleason at diagnosis PSA at baseline Ongoing treatment Total number of bone metastases
1 82 3 + 4 50 Denosumab, GnRH analogue (goserelin), calcium tablets 27
2 80 4 + 3 0.4 GnRH analogue (goserelin), calcium tablets 15
3 79 4 + 5 14 Anti-androgen (bicalutamid), GnRH analogue (goserelin) 22
4 79 5 + 4 0.5 Denosumab, GnRH analogue (goserelin), dexamethasone, calcium tablets 10
5 77 4 + 5 33 Abiraterone, denosumab, GnRH analogue (goserelin), dexamethasone, calcium tablets 29
6 77 3 + 4 96 Denosumab, GnRH analogue (goserelin), 122
7 71 3 + 4 1000 Denosumab, GnRH analogue (goserelin), prednisolone, calcium tablets 2
8 69 3 + 4 341 Abiraterone, denosumab, GnRH analogue (goserelin), dexamethasone, calcium tablets 17
9 62 5 + 4 43 Denosumab, GnRH analogue (goserelin), calcium tablets 7
10 70 5 + 5 91 Abiraterone, denosumab, prednisolone, calcium tablets 40